Crucell « Terug naar discussie overzicht

J&J neemt 18$ belang in Crucell voor 301mln

563 Posts, Pagina: « 1 2 3 4 5 6 ... 23 24 25 26 27 28 29 » | Laatste

Omlaag ↓

pardon 13 oktober 2009 14:24

J&j verhoogt de winstverwachting.

flosz 13 oktober 2009 14:31

quote:
flosz schreef:
www.investor.jnj.com/webcasts-present...

WC begonnen.

pardon 13 oktober 2009 14:36

Print Employees Careers Investors News Partners Contact Us
Print page | | Download PDF | Add to briefcase « Previous Release

Johnson & Johnson Reports 2009 Third-Quarter Results:

Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

NEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

Net earnings and diluted earnings per share for the third quarter of 2009 were $3.3 billion and $1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008. The Company raised its earnings guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes the impact of special items.

"We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth."

Worldwide Consumer sales of $4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%.

Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO(R) skin care products; SPLENDA(R) No Calorie Sweetener; Le Petit Marseillais(R) beauty care products; and LISTERINE(R) antiseptic mouthrinse. Other growth drivers were sales from the acquisition of Vania Expansion SNC.

Worldwide Pharmaceutical sales of $5.3 billion for the third quarter represented a decrease of 14.1% versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%.

REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; and RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX(R) (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL(R) (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved STELARA(TM)( ) (ustekinumab) for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA also approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults; the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. In addition, the FDA approved the Supplemental New Drug Application for INVEGA(R) (paliperidone) extended-release tablets for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants.

On Oct. 6, the European Commission approved SIMPONI(TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis.

During the quarter, the Company completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program as well as an equity investment in Elan. Additionally, the Company announced that it had entered into a licensing and collaboration agreement with Gilead Sciences, Inc., for the development and commercialization of a new fixed dose combination of investigational compound TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's TRUVADA(R) (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naive adult patients with HIV-1.

Early in the fourth quarter, the Company announced that it had entered into a strategic collaboration with Crucell, N.V., focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also included an 18% equity investment in Crucell, N.V.

Worldwide Medical Devices and Diagnostics sales of $5.8 billion for the third quarter represented an increase of 2.3% versus the prior year with an operational increase of 4.1% and a negative currency impact of 1.8%. Domestic sales increased 4.5%; international sales increased 0.5%, which reflected an operational increase of 3.8% and a negative currency impact of 3.3%.

Primary contributors to the operational growth included Ethicon's surgical care and aesthetics products; Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting strong competition in the drug-eluting stent market, and the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales... The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johns

flosz 13 oktober 2009 22:58

J&J Needs to Get Drugged Up
......
In the pipeline, Johnson & Johnson has Xarelto, a preventer of blood clots that would compete with sanofi-aventis' (NYSE: SNY) blockbuster Lovenox, but most of the potential blockbusters are farther behind. Essentially, Johnson & Johnson is in waiting mode until deals with companies such as Elan (NYSE: ELN) and Crucell (Nasdaq: CRXL) pan out.

The stock is suffering today because of the revenue miss, but long-term investors needn't worry too much. Revenue gains will return eventually, and Johnson & Johnson will cut costs, as it did this quarter, to keep earnings headed in the right direction.

www.fool.com/investing/dividends-inco...

En zo gaat ook vandaag(in de rugzak van J&J)je naam weer heel de wereld over, lekkerrrrr!
news.google.com/news/search?pz=1&cf=a...
www.bloomberg.com/apps/news?pid=20601...
finance.sina.com.cn/stock/usstock/c/2...
www.pari.bg/a/2009/10/13/Johnson__Joh...
www.investor.bg/?cat=6&id=88169
www.vg.hu/vallalatok/ipar/a-generikus...
udn.com/NEWS/WORLD/WOR2/5192905.shtml

flosz 20 oktober 2009 12:04

En ook in Turkije is men nu op de hoogte…

Johnson&Johnson ve Crucell'den işbirliği
20 Ekim 2009 - 12:14
Johnson&Johnson, merkezi Hollanda'da bulunan Crucell adlı biyoteknoloji şirketinin yüzde 18 hissesini 301.8 milyon Euro'ya alarak, dünyada inflüenzanın (grip) önlenmesi ve tedavisi de dahil olmak üzere yenilikçi ürünler geliştirmek için stratejik işbirliği yaptı.
www.stargundem.com/ekonomi/80334-john...

flosz 28 oktober 2009 11:56

Herman Saftlas, who is S&P's equity analyst for the pharmaceutical industry, agrees “vaccines have definitely become one of the brighter areas in the whole pharmaceutical waterfront.”
But, he says, with companies coming on board in a big way comes the problem of competition. Take Gardasil, for examples: Sales dropped in the latest quarter and now GlaxoSmithKline's (GSK-N40.870.561.39%) Cervarix, another HPV vaccine, is due to come into the United States soon.
But Mr. Saftlas says that Johnson and Johnson's investment in Crucell, Abbott Laboratories' new stake in Solvay and Pfizer's takeover of Wyeth all are an indication of an eagerness to get into vaccines.
“Put it this way, those that didn't have a foothold now have a foothold in vaccines; those who already had a foothold are expanding it.”
S&P has a buy rating on Johnson & Johnson, but Mr. Saftlas says vaccines have little influence in that.
The company is so large, the Crucell investment is “not going to move the needle that much.” But he says that Johnson & Johnson is not only the largest, most diversified health care companies in the world, it “one of the savviest.
“In my opinion they have had more success with their acquisitions than most of the other health care players, the large ones.”
Crucell, he adds, is just one of a long string.
Volledig art.:
www.theglobeandmail.com/globe-investo...

flosz 28 oktober 2009 13:29

October 28, 2009
You Mean You Don't Have to Buy Them?

Johnson & Johnson's CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions. And right now, that strategy is. . .not to make acquisitions. They see partnerships as making a lot more sense:

“The cost of developing compounds has become so high and become so risky that we are looking to share the risks and opportunities and find more and more partnerships.”

J&J has been putting this into practice recently, taking equity stakes in several different companies. In the case of Elan and Crucell, interestingly, the company has agreed to standstill provisions, in order to make it clear that they're not just on the first step to an outright acquisition any time soon. It's interesting that this would be coming from Johnson & Johnson, since in many cases they've been one of the less destructive acquirers in the business already. (Well, with some exceptions, like when they took over Scios).
The temptation to compare this policy with Pfizer's is almost overwhelming, but the two companies are in very different positions. For one thing, J&J has their medical devices and diagnostics businesses, which are both profitable and run on different rhythms than their pharma side. Even more importantly, they also aren't locked into a grow-or-die situation, needing larger and larger infusions of revenue to meet the expenses which get larger every time they go out and buy those revenue streams, which mean that they need to go buy some more and then. . .
The article says that J&J has no deals under consideration right now, but that this style of deal-making is definitely how the company plans to operate. There's definitely enough risk to be spread around - I just hope that there's enough reward for everyone, too.
pipeline.corante.com/archives/2009/10...

harrysnel 28 oktober 2009 14:46

Over diverse farmadeals (ook J&J):
www.fool.com/investing/general/2009/1...

[verwijderd] 28 oktober 2009 22:35

Ik ben te veel leek om te beoordelen of hier iets meer duidelijk uit wordt of dat het net zo mistig blijft op dat het non info is.

Bijlage:

harvester 28 oktober 2009 23:46

Met de huidige beursbrede daling van aandelen kan Crucell steeds meer doen met het geld van J+J.

Goed dat ze nog geen deal gesloten hebben voor een overname door Crucell.
Als ze bezig zijn met onderhandelen dan gaat dat ook ineens makkelijker.

flosz 30 oktober 2009 01:08

Prospectus, 128 p., eat your heart out!
Chapter Page
1 Summary. 2
2 Risk Factors . 8
3 Important Information . 18
4 Dividend Policy . 23
5 Use of Proceeds . 24
6 Capitalization and Indebtedness. 25
7 Selected Financial Data . 27
8 Operating and Financial Review . 29
9 Industry Overview . 49
10 Business Overview . 54
11 Management Board, Supervisory Board and Employees . 81
12 Major Shareholders. 99
13 Related Party Transactions. 102
14 Share Capital and Corporate Governance. 104
15 Taxation . 114
16 General Information . 117
17 Definitions. 119
www.crucell.com/page/downloads/271020...

[verwijderd] 30 oktober 2009 07:17

Snel lezend is het hoofdprobleem en dus waarschijnlijk ook de reden voor de koersdaling de patentissue tussen GSK en Novartis aangaande QV. Mogelijk wordt/is crucell hier zelfs rechtstreeks in betrokken.

[verwijderd] 30 oktober 2009 07:38

Nog eentje die opviel tussen alle waarschuwingen:

groter risico op overname (vijandig) door volatiele (lees lage) beurskoers.

[verwijderd] 30 oktober 2009 08:40

quote:
callhans schreef:
Snel lezend is het hoofdprobleem en dus waarschijnlijk ook de reden voor de koersdaling de patentissue tussen GSK en Novartis aangaande QV. Mogelijk wordt/is crucell hier zelfs rechtstreeks in betrokken.

Op blz 76 (laat Ron het maar niet lezen):

"In addition, production of Quinvaxem requires a particular vaccine component that may become the subject of a patent dispute between either GSK and us or GSK and our supplier of that component. The patent on that particular component, held by GSK, is currently under opposition before the patent office and a definitive outcome on the validity of the patent is expected to take a number of years. A negative outcome of this opposition proceeding could lead to infringement proceedings between GSK and us or GSK and our supplier, although we believe that neither we nor our supplier would be held to have infringed or be infringing that patent. The outcome of legal disputes is invariably difficult to predict with accuracy, but if GSK were to prevail in infringement proceedings against us, this would adversely affect our business."

Het lijkt erop of GSK na de eerdere patentdisputen (2005-2008) rond pentavalent, waarbij een patent niet is gebleken, alsnog een rondje wil ruzieën met Novartis/Crucell.

[verwijderd] 30 oktober 2009 09:13

zo prospectus uit (mooi leeswerkje voor een regenachtige zondag), aandelen waarschijnlijk per vandaag genoteerd, cash per ???? te besteden ?

Mooi weekend om nog wat te regelen. De sheetpresentatie voor dinsdag is toch al uitgeprint dus best wat tijd over Ron ea.

Mr sponge 30 oktober 2009 09:43

Idd leesvoer voor komend weekend.
Voor de mensen die wachten op dividend:

"Dividends: We do not anticipate paying any dividends for the foreseeable future." (Pag. 5)

Zoals Crucell al eerder had aangegeven. Dus zijn we voorlopig van deze discussie af.

flosz 30 oktober 2009 10:16

quote:
callhans schreef:
Snel lezend is het hoofdprobleem en dus waarschijnlijk ook de reden voor de koersdaling de patentissue tussen GSK en Novartis aangaande QV. Mogelijk wordt/is crucell hier zelfs rechtstreeks in betrokken.

2008
P.74
hugin.info/132631/R/1312469/304318.pdf

2007
P. 62
hugin.info/132631/R/1219439/255908.pdf

[verwijderd] 30 oktober 2009 10:27

Ja, had het daar (2008) ook al gelezen, maar denk toch dat daar de reden ligt voor de neerwaartse koersdruk. Ook omdat insiders beter weten hoe het ervoor staat dan normale aandeelhouders.

Sir Piet 30 oktober 2009 10:53

quote:
callhans schreef:
Ja, had het daar (2008) ook al gelezen, maar denk toch dat daar de reden ligt voor de neerwaartse koersdruk. Ook omdat insiders beter weten hoe het ervoor staat dan normale aandeelhouders.

Iemand moet van zijn stukken af denk ik. We zaggen paar weken geleden al een melding, ben benieuwd wanneer de volgende komt.

harvester 30 oktober 2009 23:10

quote:
Sir Piet schreef:
[quote=callhans]
Ja, had het daar (2008) ook al gelezen, maar denk toch dat daar de reden ligt voor de neerwaartse koersdruk. Ook omdat insiders beter weten hoe het ervoor staat dan normale aandeelhouders.
[/quote]

Iemand moet van zijn stukken af denk ik. We zaggen paar weken geleden al een melding, ben benieuwd wanneer de volgende komt.

Dat zouj best een de verklaring voor de spike kunnen zijn. Willen verkopen maar niet tegen elke prijs.

563 Posts, Pagina: « 1 2 3 4 5 6 ... 23 24 25 26 27 28 29 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 937,58 0,00 0,00% 21 feb


Germany40^	22.458,90	+0,77%
BEL 20	4.405,39	0,00%
Europe50^	5.485,88	+0,20%
US30^	43.593,80	+0,39%
Nasd100^	21.703,80	+0,40%
US500^	6.041,04	+0,44%
Japan225^	38.350,10	+0,52%
Gold spot	2.940,09	+0,15%
EUR/USD	1,0510	+0,33%
WTI	70,28	+0,13%